Atlas Trials

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Clinical trial NCT03308396 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03308396
Sponsor
Ajjai Alva, MD
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Kidney CancerKidney CancerClear Cell Renal Cell Carcinoma
Start date
2017-12-19
Primary completion
2022-12-01
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.